+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs



EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs



European Journal of Cancer and Clinical Oncology 24(9): 1535-1538




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039886677

Download citation: RISBibTeXText

PMID: 3181274

DOI: 10.1016/0277-5379(88)90349-5


Related references

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. British Journal of Cancer 72(1): 210-218, 1995

Development of an intravenous formulation for the unstable investigational cytotoxic nucleosides 5-azacytosine arabinoside (NSC 281272) and 5-azacytidine (NSC 102816). Journal of Pharmacy and Pharmacology 36(11): 728-733, 1984

ASHP guidelines for the use of investigational drugs in institutions. American Journal of Hospital Pharmacy 36(2): 221-222, 1979

Guidelines for the procurement of investigational and emergency drugs. Canadian Journal of Hospital Pharmacy 41(5): 275-276, 1988

ASHP guidelines for the use of investigational drugs in organized health-care settings. American Journal of Hospital Pharmacy 48(2): 315-319, 1991

Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10 Suppl 1: S263-S270, 1994

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Annals of Oncology 13(8): 1300-1306, 2002

Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas. Journal of Urology 162(6): 2200-2204, 1999

EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. European Journal of Cancer & Clinical Oncology 21(9): 1005-1007, 1985

Proposed guidelines for validating serum and plasma protein binding utilizing ultrafiltration Case studies with investigational drugs. Pharmaceutical Research (New York) 13(9 SUPPL ): S421, 1996

Dispensing investigational drugs: regulatory issues and the role of the investigational drug service. American Journal of Health-System Pharmacy 61(18): 1882-1884, 2004

Chemical control information on investigational drugs required for an investigational new drug application (I.N.D.). American Journal of Hospital Pharmacy 26(3): 178-179, 1969

Gaining access to investigational drugs for treatment: an investigational new drug application primer. International Journal of Pharmaceutical Compounding 6(4): 271-273, 2002

Charging for investigational drugs under an investigational new drug application. Final rule. Federal Register 74(155): 40871-40900, 2009

The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. British Journal of Haematology 165(1): 78-88, 2014